Loading...

CYPH CYPHERPUNK TECHNOLOGIES INC Business Restructuring 8-K Filing

CYPH

CYPH

CYPHERPUNK TECHNOLOGIES INC

(CYPH)

2023 8-K

Financial Results Announced

Delisting Notice

Stock Award Adjustment

Zcash Acquisition

Shareholder Meeting Results

Warrant Modification

Zcash Acquisition

Name Change & Offering

Name Change Announcement

Funding Agreement Details

Private Placement Announcement

Delisting Notification

Financial Results Announcement

Reduction in Force

Financial Statements

Financial Results

Nasdaq Notification

Clinical Data Release

Financial Results

Study Enrollment Complete

Financial Results

Annual Meeting Results

Financial Results Announcement

Private Placement Agreement

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Reverse Stock Split

Financial Results Announcement

Amendment to Employment Agr...

Financial Results Announcement

Agreement Expiration and Co...

Acquisition of Flame Biosci...

External Links:

Leap Therapeutics and BeiGene have entered into a letter agreement, expiring BeiGene's option to obtain an exclusive license for Leap Therapeutics' anti-DKK1 monoclonal antibody, but continue to collaborate on a clinical trial and perform their respective obligations under existing agreements.

AI Assistant

CYPHERPUNK TECHNOLOGIES INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.